160 related articles for article (PubMed ID: 26974274)
1. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Ong SY; de Mel S; Chen YX; Ooi MG; Surendran S; Lin A; Koh LP; Linn YC; Ho AY; Hwang WY; Phipps C; Loh SM; Goh YT; Tan D; Chng WJ; Gopalakrishnan SK
Bone Marrow Transplant; 2016 Jul; 51(7):933-7. PubMed ID: 26974274
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
3. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
5. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
6. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
7. Complete response after autologous stem cell transplant in multiple myeloma.
Kumar L; Iqbal N; Mookerjee A; Verma RK; Sharma OD; Batra A; Pramanik R; Gupta R
Cancer Med; 2014 Aug; 3(4):939-46. PubMed ID: 24777883
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
Martinez-Lopez J; Blade J; Mateos MV; Grande C; Alegre A; García-Laraña J; Sureda A; de la Rubia J; Conde E; Martinez R; de Arriba F; Viguria MC; Besalduch J; Cabrera R; Gonzalez-San Miguel JD; Guzman-Zamudio JL; Gomez del Castillo MC; Moraleda JM; García-Ruiz JC; San Miguel J; Lahuerta JJ; ;
Blood; 2011 Jul; 118(3):529-34. PubMed ID: 21482708
[TBL] [Abstract][Full Text] [Related]
12. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
13. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
[TBL] [Abstract][Full Text] [Related]
15. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Pasvolsky O; Marcoux C; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Tewari P; Crawford-Suber L; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Br J Haematol; 2023 Aug; 202(4):866-873. PubMed ID: 37376789
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
Garderet L; Sbianchi G; Iacobelli S; Blaise D; Byrne JL; Remenyi P; Apperley JF; Touzeau C; Isaksson C; Browne P; Mayer J; Lenhoff S; Gonzalez Muniz S; Parody Porras R; Basak G; Poire X; Trneny M; Nagler A; Michieli M; Tanase A; Koster L; Hayden PJ; Beksac M; Schönland S; Yakoub-Agha I
Eur J Haematol; 2021 May; 106(5):708-715. PubMed ID: 33580608
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.
Kumar L; Gundu N; Kancharia H; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma O; Biswas A; Kumar R; Thulkar S; Mallick S;
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):80-90.e5. PubMed ID: 33129746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
